Institutional members access full text with Ovid®

Share this article on:

Efficacy and Safety of Lisdexamfetamine Dimesylate [LDX; NRP104] in Children Aged 6 to 12 Years with Attention-Deficit/Hyperactivity Disorder

Biederman, Joseph1; Mandler, Hilary2; Krishnan, Suma3; Findling, Robert L.4

Journal of Developmental & Behavioral Pediatrics: October 2006 - Volume 27 - Issue 5 - p 443
Abstracts: Abstracts of Papers Accepted for Presentation at the Annual Meeting of the Society for Developmental and Behavioral Pediatrics: Poster Session, Sunday, September 17, 2006, 6:00 p.m. - 7:00 p.m.: Abstract # 44

1Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; 2Shire Development Inc, Wayne, PA; 3New River Pharmaceuticals Inc, Blacksburg, VA; 4Case Western Reserve University, Cleveland, OH.

© 2006 Lippincott Williams & Wilkins, Inc.